



# VIRTUAL UK ONCOLOGY FORUM 2021

## THE FORTHCOMING OPENING OF THE RECORDED VERSION OF THE UK ONCOLOGY FORUM AGENDA

To Open on Tuesday 7th December 2021 to Friday 7th January 2022

To receive a CPD certificate you must attend:

At least 3 clinical sessions (eg Lung, Melanoma, Radiotherapy) etc.

Both keynote lectures

The Covid/Cancer discussion

The platform will monitor individual attendees “conference foot-print”. The secretariat is duty bound to ensure that all healthcare professionals attend the sessions, to be awarded CPD. Programme evaluation is compulsory, certificates will ONLY be awarded if all evaluations are completed.

**CME accreditation is NOT awarded for Industry Symposia.**

Industry Symposia will **NOT** be run parallel to the UKOF programme.

## SUBJECT

### UKONS – Sexual Health and Cancer 2 - all registered OF21 HCPs Welcome

Welcome and introduction to the UKONS session	Kay Bell, UKONS Board member
Introduction to Penile Cancer	Shievon Smith & Michelle Greenwood, Uro-Oncology CNS Barts Health
Penile Cancer unmet needs	Rob Cornes CNS Orchid Male Cancer Charity
Psychosexual Needs and Cancer	Psychosexual CNS Lorraine Grover, Harley Street Clinic
Introduction for female sexual health and Cancer	Shievon Smith & Michelle Greenwood, Uro-Oncology CNS Barts Health
Patient perspective of sex and cancer	Anita Brown, Bladder Cancer Patient
Panel discussion with Q&A	Michelle Greenwood, Shievon Smith & Anita Brown

UKONS would like to thank the Champions Shievon Smith and Michelle Greenwood for organising this session

### Notch AGM – all registered OF21 HCPs Welcome

Introduction - Overview of the past 12 months	Dr Caroline Dobeson / Dr Mark Baxter
NOTCH Showcase: Clinical Features, Management & Outcomes of Patients with Thymic Epithelial Neoplasia: a UK Multi-Centre Series	Dr Abigail Gault
NOTCH Showcase: Real-world Outcomes of Immune-related Adverse Events in 2125 Patients Managed with Immunotherapy: a UK Multi-Centre Series	Dr Anna Olsson-Brown
Announcement of board positions for upcoming year	Dr Caroline Dobeson
Research Symposium – 2022	Dr Mark Baxter
Future directions...	

SUBJECT
<b>BAYER PROSTATE SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
<b>MERCK PFIZER ALLIANCE RENAL SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
<b>NOVARTIS PLATINUM SPONSOR BREAST SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)</b>
EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)
<b>UKOF OPENS ~ WELCOME &amp; INTRODUCTION – CHAIR: PROFESSOR RUTH PLUMMER</b>
<b>OPENING KEYNOTE SPEAKER – PROFESSOR LINDA BAULD</b> Cancer prevention and Covid-19: How do we align communicable and non-communicable disease responses as part of Covid recovery?
EXHIBITION & CHARITY CORNER (PLEASE VISIT THE VIRTUAL STANDS)

SUBJECT	
<b>BREAST BREAKOUT – CHAIRS: DR MARINA PARTON &amp; DR MARK VERRILL</b>	
Welcome and introduction	<i>Dr Marina Parton &amp; Dr Mark Verrill</i>
NCRI update and roles of CSF	<i>Mr Stuart McIntosh</i>
Conference updates	<i>Dr Olga Oikonomidou</i>
Fast Forward	<i>Professor Murray Brunt</i>
A year on covid	<i>Ms Karen Verrill</i>
ESMO data	<i>Dr Suzette Delaloge</i>
Q+A	<i>All faculty</i>
Summary and closure	<i>Dr Marina Parton &amp; Dr Mark Verrill</i>
<b>COLORECTAL BREAKOUT – CHAIR: DR VICKY COYLE</b>	
Welcome and introduction	<i>Dr Vicky Coyle</i>
Highlights of ASCO/ESMO	<i>Dr Lizzy Smyth</i>
Total neoadjuvant therapy for rectal cancer	<i>Dr Sean O'Cathail</i>
Systemic therapy for MSI-H CRC	<i>Dr Kai Keen Shiu</i>
Optimising MDM management for CRC survivors	<i>Professor Katherine Van Loon</i>
Q+A	<i>All faculty</i>
Summary and closure	<i>Dr Vicky Coyle</i>
<b>GYNAECOLOGY – CHAIR: DR YVETTE DREW</b>	
Welcome and Introductions	<i>Dr Yvette Drew</i>
Targeting High Grade Serous Ovarian Cancer Beyond PARPi	<i>Dr Stephanie Lheureux</i>
Novel follow-up strategies in Gynaecological Cancers	<i>Dr Esther Moss</i>
Cervical cancer advances and current UK trial portfolio	<i>Dr Rebecca Bowen</i>
The challenges and future directions of surgical trials in gynaecological oncology	<i>Professor Christina Fotopoulou</i>
ESMO 2021 Gynae -the Professors round-up	<i>Professor Iain McNeish</i>
Panel Q and A session	<i>All speakers and Chair</i>
Summary and closing remarks	<i>Dr Yvette Drew</i>

SUBJECT	
<b>HEAD &amp; NECK BREAKOUT – CHAIR DR CHARLES KELLY</b>	
Welcome and introduction	<i>Dr Charles Kelly</i>
Reirradiation AND head and neck	<i>Dr Shahid Iqbal</i>
The clinical consequences of HPV in H&N clinics in 10 years	<i>Dr Kate Cuschieri</i>
Where we will be in H&N surgery in ten years' time	<i>Professor Vinidh Paleri</i>
"The next 10 years in H&N Systemic Therapy	<i>Professor Paolo Bossi</i>
Q+A	<i>All faculty</i>
Summary and closure	<i>Dr Charles Kelly</i>
<b>LIVER &amp; PANCREATIC BREAKOUT - CHAIRS: MS ANITA BALAKRISHNAN &amp; PROFESSOR DEREK O'REILLY</b>	
Welcome and introduction	<i>Ms Anita Balakrishnan &amp; Professor Derek O'Reilly</i>
Enriching the pool of patients with pancreatic cancer that benefit from chemotherapy, in particular clinical trials such as POLO that used this approach	<i>Professor Eileen M. O'Reilly</i>
How to conduct surgical trials in pancreatic cancer	<i>Professor Chris Halloran</i>
Advance in the treatment of colorectal liver metastases	<i>Professor Jean Nicolas Vauthey</i>
Novel advances in the systemic and locoregional treatments for cholangiocarcinoma	<i>Dr Thankamma Ajith Kumar</i>
Summary and closure	<i>Ms Anita Balakrishnan &amp; Professor Derek O'Reilly</i>

**SUBJECT****LUNG BREAKOUT – CHAIR: PROFESSOR SAMREEN AHMED*****The ever-changing landscape of early and advanced NSCLC***

Welcome and introduction

***Professor Samreen Ahmed***

Update on advanced non-oncogene driven NSCLC: pivotal studies leading to current practice and then allude to perioperative treatment being the direction of travel with immunotherapy given adjuvantly

***Dr Tom Newsom-Davis***

Update on advanced oncogene driven NSCLC: : pivotal studies leading to current practice and then allude to perioperative treatment being the direction of travel with osimertinib given adjuvantly for potential cure:

***Dr Riyaz Shah***

Panel Q and A session

***All speakers and Chair***

The advantages and pitfalls of genomic testing in lung cancer: development of genomic hubs and their purpose, how is genomic testing being rolled out and when will NGS be available in lung cancer for the majority of the country. Concept of the test directory:

***Dr Rachel Butler***

Panel Q and A session

***All speakers and Chair***

Update on radiotherapy advances in NSCLC (all stages): present pivotal studies leading to current practice and some discussion of oligomet treatments and outcomes:

***Dr Sridhar Thiagarajan***

Perioperative therapies: A surgical perspective: surgical outcomes for patients receiving chemotherapy/immunotherapy/radiotherapy. Some discussion of stage 3 operability:

***Mr Sridhar Rathinam***

Panel Q and A session

***All speakers and Chair***

Summary and closure

***Professor Samreen Ahmed***



SUBJECT		
<b>MELANOMA BREAKOUT – CHAIR: DR SAMRA TURAJLIC</b>		
Welcome and introduction		<i>Dr Samra Turajlic</i>
Where next for uveal melanoma?		<i>Professor Richard Cavajal</i>
Q&A		<i>All</i>
"New principles of integrating surgical and systemic therapy in melanoma"?		<i>Dr Alexander van Akkooi</i>
Q&A		<i>All</i>
Symptomatic brain metastases: curing the incurable?		<i>Dr Kim Margolin</i>
Q&A		<i>All</i>
ASCO/ESMO update		<i>Professor James Larkin</i>
Q&A		<i>All</i>
Panel discussion/debate		<i>All Faculty</i>
Wrap up & close		<i>Dr Samra Turajlic</i>
<b>PROSTATE BREAKOUT – CHAIR PROFESSOR NICK VAN AS</b>		
Welcome and introduction		<i>Professor Nick Van As</i>
MRI in PCa, when to use, how to scan, what to look for?		<i>Dr Clare Allen</i>
Metastasis directed therapy, when, how, what next?		<i>Professor Piet Ost</i>
Surgery in high risk and metastatic disease. Should we be doing it?		<i>Professor Noel Clarke</i>
Where to next fix systemic therapy in castrate sensitive PCa		<i>Professor Christopher Sweeney</i>
Panel Q+A		<i>All faculty</i>
Summary and closure		<i>Professor Nick Van As</i>
EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)		
<b>THE BIG COVID CANCER/CANCER DISCUSSION – CHAIR PROFESOR DANIEL HOCHHAUSER</b>		
Panel: <i>Dr Phil Hammond, Professor Linda Bauld &amp; Professor Peter Openshaw</i>		

**SUBJECT****JANSSEN-CILAG PROSTATE SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)****BAYER PAN TUMOUR SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)**

EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)

**ACUTE ONCOLOGY BREAKOUT - CHAIR: DR ERNIE MARSHALL**

*The establishment of acute oncology services was first recommended in 2009 as an NHS requirement for all Hospital Trusts with an A&E department. Since its inception, acute oncology has become widely established across the country, leading to improvements in safety and quality of unplanned cancer care. However, despite this progress, there remains distinct variation in access to specialist advice with many teams only able to deliver 5 day service. Traditional acute oncology has focussed largely on inpatient care and neutropenic sepsis at a time of rapidly changing cancer care and urgent care transformation.*

*Acute Cancer care is much bigger than traditional acute oncology and is a major component of the wider urgent care system – a system that remains under intense pressure exacerbated by the COVID pandemic.*

*Late presentation of new cancers, treatment complications and cancer progression in an aging and multi-morbid population will require a system response in which Oncology must work ever more closely with urgent care partners. Acute Cancer presentation and service redesign will demand ever greater oncology leadership and vision if sustainable change is to be achieved. This approach should include novel approaches to reduce late presentation, management pathways that support networked services, greater access for same day emergency care (SDEC) and a greater focus on acute cancer research.*

*The UK Oncology Forum inaugural Acute Oncology session will aim to show case some of the AO innovation that is taking place and highlight the need to develop a future AO workforce and leadership structure that ensures Oncology is an effective collaborative partner to the wider urgent care system.*

Welcome and Introduction

*Dr Ernie Marshall*

Acute Oncology and Early Diagnosis: Oncology led Rapid Diagnostic Services

*Dr Saoirse Dolly*

Digital Acute Oncology: lessons from COVID

*Dr Caroline Wilson*

Cancer Centre Acute Oncology: The Acute Medicine Interface

*Dr Tim Cooksley*

The Cancer Unit: Nurse Delivered AO in the real World

*Ms Naomi Clatworthy / Ms Christine Rhall*

I-O Toxicity Update

*Dr Anna Olssen Brown*

Acute Oncology Careers: A joint voice from RCR/RCP and UKONS

*Dr Robert Stuart*

Q&amp;A and wrap up

*All Faculty*



**SUBJECT****BASO BREAKOUT - CHAIR: MR ZAED HAMADY***Recent insight into surgical oncology practice*

Welcome and introduction	<i>Mr Zaed Hamady</i>
Surgical Management of Neuroendocrine Tumours	<i>Mr Tom Armstrong</i>
Q&A	<i>All</i>
Liver transplantation for cancer, future trend?	<i>Mr Raj Prasad</i>
Q&A	<i>All</i>
Robotic HPB cancer surgery, the way for the future or optimistic	<i>Mr Gabrielle Marangoni</i>
Q+A	<i>All</i>
Panel discussion	<i>Panel discussion</i>
Summary and closure	<i>Mr Zaed Hamady</i>

**BRAIN METASTASES AND GLIOMAS BREAKOUT - CHAIR: DR CATHERINE MCBAIN**

In this session, we will review advances in the management in primary and secondary brain tumours, with a particular focus on the role of steroids and the interplay with immunotherapy. The session will be cross-cutting, spanning the evidence base while interrogating when, why and how we use dexamethasone and how we can ensure we are achieving benefits while minimising complications. Using real-life case histories, we will discuss advances in the treatment of primary malignant gliomas and, taking melanoma as our example, interrogate all the options (neurosurgery, stereotactic radiotherapy, whole brain radiotherapy and systemic therapy) for brain metastases. We will describe how we can protect our patients from steroid-induced harm, focusing particularly on bone health and diabetes, and discuss the important recently released 2021 National Patient Safety Alert around dexamethasone. We will close by asking whether there are any viable alternatives to steroid use. The session will be interactive and will be of relevance to any health care professional who encounters patients with primary or secondary brain tumours in primary care, secondary care, acute oncology or tertiary centres.

Welcome and introduction	<i>Dr Catherine McBain</i>
Primary brain tumours: current management and the truth about steroid requirements	<i>Professor Susan Short</i>
Immunotherapy in Neuro-Oncology	<i>Professor Dr Michael Weller</i>
Secondary brain tumours: multidisciplinary management	<i>Professor Paul Lorigan</i>
Minimising complications of steroid use	<i>Dr Janhoong Ho</i>
Alternatives to steroids – are there any?	<i>Dr Gerben Borst</i>
Review quiz and Q+A	<i>All faculty</i>
Summary and closure	<i>Dr Catherine McBain</i>



## SUBJECT

### MACMILLAN GP SESSION BREAKOUT - DAY – CHAIR: DR ANTHONY CUNLIFFE

#### ***'Personalised care and cancer- it's everyone's business'***

*Ensuring that people living with cancer receive personalised care is everyone's business, with touchpoints from the point of diagnosis, through to prehab, treatment decisions, acutely unwell episodes, good quality cancer care review conversations, needs assessments, gaining support from social prescribers and courageous end of life care conversations. The COVID-19 pandemic has notably impacted patient care over the past 12-18 months, with changes to ways of working, huge reductions in patients presenting with signs or symptoms of cancer and changes or delays to treatment plans due to infection risk. All of these changes have had an impact on the ability of health and care Professionals to continue to ensure the delivery of good quality personalised care for people living with cancer.*

*In this workshop, we'll explore the impact of the pandemic on the delivery of personalised care for people living with cancer and will consider how we can sustain positive changes to ways of working and innovative adaptations to delivery of care developed through the pandemic, whilst ensuring that inequalities are not exacerbated as a result. This session will bring together a multi-Professional team to consider how we can build on the strengths of different Professionals involved in delivering care to people following a cancer diagnosis. Through the use of case studies, we'll generate an interactive conversation based around the key times of need experienced by cancer patients to draw out what each individual can bring to achieving personalised care supported by evidence and insight throughout.*

***Speakers: Dr Anthony Cunliffe (Chair), Dr Ashling Lillis, Ms June Davis***

**SUBJECT****RADIOTHERAPY BREAKOUT - CHAIR DR FIONA MCDONALD**

Welcome and Introduction	<i>Dr Fiona McDonald</i>
The future of hypo-fractionated treatments – What lessons can be learnt from FAST FORWARD?	<i>Professor Charlotte Coles</i>
The future of the UK Proton Programme – Where are we in 2021 and what are future plans?	<i>Dr Romelie Rieu</i>
Coffee break	
The future of drug-radiation studies – Lessons learnt from developing CONCORD?	<i>Dr Alastair Greystoke</i>
The future of UK SABR – Challenges of national rollout and ongoing research	<i>Dr John Conibear</i>
Panel discussion	<i>All</i>
Summary and close	<i>Dr Fiona McDonald</i>

**RENAL & BLADDER BREAKOUT - CHAIRS: PROFESSOR ALISON BIRTLE & PROFESSOR PETER HOSKIN*****'The Bladder/Renal Jigsaw : Putting the pieces together'***

Welcome and introduction	<i>Professor Alison Birtle &amp; Professor Peter Hoskin</i>
Surgical areas of controversy in urothelial cancer	<i>Miss Jo Cresswell</i>
What is needed in bladder/renal cancer from patient perspective	<i>Ms Shievon Smith</i>
Metastatic and urothelial cancer. How has the world changed in 2021? Did practice change during covid-1	<i>Professor Syed Hussein</i>
MRI in bladder cancer avoiding TURBT	<i>Professor Nicholas James</i>
ESMO/ASCO/ASCO GU update	<i>Professor Syed Hussein</i>
Imaging of urothelial cancers including TTCs of the kidney	<i>Dr Ben Taylor</i>
Stereotactic and more!	<i>Dr Kate Fife</i>
Panel discussion	<i>All</i>
Summary and close	<i>Professor Alison Birtle &amp; Professor Peter Hoskin</i>

**SUBJECT****TREATING THE OLDER CANCER PATIENT BREAKOUT - CHAIR: PROFESSOR KWOK-LEUNG CHEUNG**

Welcome and introduction	<i>Professor Kwok-Leung Cheung</i>
Prehabilitation – using hepatobiliary malignancy as an example	<i>Mr Nicola de' Liguori Carino</i>
ASCO updates	<i>Dr Antonella Brunello</i>
The impact of Covid-19 on older patients with cancer	<i>Dr Giuseppe Colloca</i>
Q+A	<i>All faculty</i>
BREAK	
Difficult and challenging cases – MDT discussion	<i>Dr Lisa Rodgers and Dr Anthea Cree (co-leads) and all faculty</i>
Q+A	<i>All faculty</i>
Summary and closure	<i>Professor Kwok-Leung Cheung</i>

**UKOMIC BREAKOUT - CHAIR: DR CHARLES KELLY**

Welcome and introduction	<i>Dr Charles Kelly</i>
Oral health in head and neck cancer patients	<i>Dr Gerry Mckenna &amp; Dr Ciaran Moore</i>
Q&A	<i>All faculty</i>
Nordic Team presenting guidance on oral health after cancer and cancer treatments	<i>Ms Elisabeth Wallhult, Ms Lea Brandt Kristensen &amp; Ms Ann-Mari Berthelsen</i>
Q&A	<i>All faculty</i>
Oral case study	<i>Dr Barry Quinn</i>
Q&A	<i>Dr Charles Kelly</i>
Updates on trials in cancer and oral health	<i>Dr Charles Kelly</i>
Panel discussion	<i>All faculty</i>
Summary & close	<i>Dr Charles Kelly</i>

## SUBJECT

### UKONS BREAKOUT – CHAIR: MS TRACY WILSON

**Title-** Prehabilitation and beyond: Preparing for the future

**Aims-**

- Identify the rationale for prehabilitation and rehabilitation
- Identify workforce opportunities
- Demonstrate an evidence base for service development

**Sessions-**

1. Behaviour change- universal interventions
2. Non-specialist workforce- utilising existing workforce
3. Specialist interventions- developing specialist services
4. Building a business case- how to pitch your argument!
5. Panel discussion

Introduction - why think about prehab? What's it all about?

*Ms Tracy Wilson*

Behaviour change in practice - **more than meets the eye. The SafeFit model**

*Ms Judit Varkonyi-Sepp*

Non-specialist workforce - **example of how non-specialist prehab practitioners incorporated into their practice**

*Ms Jo McNamara / Ms Hazel Pennington*

Specialist interventions - **when you need that bit more. Case study on setting up the specialist prehab/rehab service in Sheffield**

*Mr Liam Humphreys*

Building a business case - **what do you need to make an impact? How can you persuade others to make a system change?**

*Mr Jason Tong / Ms Shana Hall*

Panel discussion

*All*

Closing remarks

*Ms Tracy Wilson*

**SUBJECT****UPPER GI BREAKOUT - CHAIRS: PROFESSOR RUSSELL PETTY & DR JANET GRAHAM**

*The last 12 months have provided us with a series of positive trials in gastroesophageal cancer providing new treatment options for our patients. This session will provide updates from these practice changing studies reported in 2021, straight from the chief investigators themselves and combine this with a real-world perspective of the challenges of managing gastroesophageal cancer patients in practice. We will discuss how the latest trial outcomes can be applied to make optimal treatment choices for individual patients in the advanced and early-stage settings, for systemic, radiotherapy and surgical treatment.*

Welcome and introduction

*Professor Russell Petty & Dr Janet Graham*

Decision making in peri-operative treatment of gastroesophageal cancer - what have we learnt from the neo-Aegis Trial

*Professor John Reynolds*

Defining the optimal role for checkpoint inhibitors in the perioperative treatment of gastroesophageal cancer

*Dr Lizzy Smyth*

Optimising the systemic treatment of older and frailer patients with advanced gastroesophageal cancer

*Professor Matt Seymour*

Checkmate 648 and the emerging role for Immunotherapy in Advanced Squamous cTII carcinoma Oesophagus

*Dr Ian Chau*

The state the art treatment of advanced gastroesophageal adenocarcinomas (including ASCO and ESMO updates)

*Dr Yelena Janjigian*

Q+A

*All Faculty*

Summary and closure

*Professor Russell Petty & Dr Janet Graham*

EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)

**CLOSING KEYNOTE SPEAKER – PROFESSOR SAM JANES ~ UKOF CLOSES**

EXHIBITION (PLEASE VISIT THE VIRTUAL STANDS)

**PIERRE FABRE MELANOMA SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)**

**PIERRE FABRE CRC SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)**

**SEAGEN – BREAST SPONSORED SYMPOSIUM (CME NOT AWARDED TO INDUSTRY SYMPOSIA)**



## Secretariat

Athena Meetings & Events

AXIS, Jordangate House

Jordangate

Macclesfield

England

SK10 1EQ

## Contact Details

Sharon Poole [sharon@athenameetings.com](mailto:sharon@athenameetings.com)

Lisa Young [lisa@athenameetings.com](mailto:lisa@athenameetings.com)

Jak Poole [jak@athenameetings.com](mailto:jak@athenameetings.com)